Pliant Therapeutics Inc (PLRX) Stock AnalysisPLRXStock AnalysisPliant Therapeutics Inc

Pliant Therapeutics, Inc. is a late-stage biotechnology company, which is focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Pliant Therapeutics Inc is not a strong buy right now due to its current price of $1.11, which is significantly below the analyst price target of $3. The company has a negative forward P/E ratio of 0, indicating that it is not generating profits at this time, and the RSI of 42.609 suggests it is nearing oversold territory. However, the recent insider buying activity and a strong cash position of $192.4 million, projected to fund operations into 2028, provide some support. The main risk is its declining net income, which has been negative for several quarters, with the latest reported at -$22.37 million for Q2 2026.